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Intensive Diabetes Management for
High-Risk Patients: How Best to Deliver?
T
ype 2 diabetic patients with mi-
croalbuminuria or more advanced
chronic kidney disease are at ex-
tremely high risk of cardiovascular dis-
ease (CVD) and end-stage renal disease
(ESRD),withtheriskofbothincreasingas
kidneydiseaseprogresses.CVDandrenal
disease share many risk factors. The
Steno-2 study demonstrated that inten-
sive structured care, targeting these risk
factors aggressively, slowed progression
of nephropathy and retinopathy and re-
duced cardiovascular death in type 2 dia-
betic patients with microalbuminuria by
40–60% (1–3).
In this issue of Diabetes Care, Chan et
al. (4), for the Structured Versus Usual
Care on Renal Endpoint in Type 2 Diabe-
tes (SURE) Study Group, provide further
evidenceofthebeneﬁtsofintensivetarget-
driven care and raise questions as to how
best to deliver such care. They compared
structured care, including a predeﬁned
protocolandtighttreatmenttargetsdeliv-
ered by a diabetologist-led specialist
team, with usual care, delivered by spe-
cialists or nonspecialists. The study was
conducted in nine hospitals; 205 type 2
diabetic patients, aged 35–75 years with
plasma creatinine 150–350 mol/l, were
randomized, and 167 completed the
2-year study. The main reasons for with-
drawal included death (n  19) and re-
ferral to nephrology for dialysis (n  14).
The number of patients reaching the pri-
mary end point (death or ESRD, deﬁned
as a need for dialysis or having plasma
creatinine 500 mol/l) was similar in
thetwogroups,aswasthenumberofclin-
ical events, hospital admissions, and
emergency room visits. However, after 2
years, the structured care group had
lower diastolic blood pressure and A1C
and was more likely to attain 3 treat-
ment goals than was the usual care group
(61% [n  63] vs. 28% [n  28], respec-
tively). In a per-protocol analysis, there
was a 60% risk reduction in reaching the
primary end point for patients who
achieved 3 treatment goals compared
withthosewhodidnot(14vs.34;relative
risk 0.43 [95% CI 0.21–0.86]).
The major strengths of this study are
the inclusion of type 2 diabetic patients at
extremelyhighriskofCVDandESRDand
the design of the structured care arm.
Structured care, delivered by a multidis-
ciplinary team of diabetes specialists, en-
compassed prespeciﬁed care plans, tight
treatmenttargets,frequentvisits,ongoing
education and counseling, and a pre-
printed case-report book to prompt clini-
cian action. The study demonstrates
clearly that those receiving structured
careweremorelikelytoachieve3treat-
ment targets and showed a strong rela-
tionship between the number of targets
achieved and outcome. However, the
study was underpowered: the observed
primary outcome rate was approximately
half that expected from the Asian sub-
group of the Reduction of Endpoints in
NIDDM with the Angiotensin II Antago-
nistLosartan(RENAAL)study(5)andan-
other small local pilot study (6). Thus,
diabetes care generally in Hong Kong
SAR, China, may have improved. Usual
care was provided by diabetes specialists
ornonspecialistsaccordingtotheindivid-
ual clinic’s usual practice rather than be-
ing prescribed. Clearly, in at least some of
these usual care clinics, particularly those
run by diabetes specialists, management
was aggressive and many tight targets
were reached. This contamination con-
tributed to the failure to establish a clear
superiority of structured care in improv-
ing outcome. However, this is real-life; it
would be virtually impossible, and per-
haps now even unethical, to randomize
high-risk individuals to less active care.
What implications does this report
have for the management of high-risk
type 2 diabetic patients? First, there is
now a wealth of evidence that type 2 dia-
betes management is no longer simply
about glucose. The UK Prospective Dia-
betes Study showed the independent and
additiveeffectsofglucoseandbloodpres-
sureonthedevelopmentofmicrovascular
and macrovascular complications (7). A
similar 5-year observational study dem-
onstrated that the more treatment targets
reached at baseline, the less likely the risk
ofnew-onsetCHD(8).TheSteno-2study
(1–3) and the SURE study attest to the
vital importance of addressing many fac-
tors simultaneously. The higher the num-
ber of targets reached, the better the
outcome: patients achieving 3 targets
faredbetterthanthoseachieving2.Sec-
ond, what is good for the macrovascular
system also seems good for the microvas-
culature: in the Steno-2 study, the risk
reduction for CVD end points was similar
to the reduction for progression of ne-
phropathy and retinopathy (2,3). Third,
even in a clinical trial setting, it is difﬁcult
to achieve these tight targets. In the
Steno-2 study, 16–75% of patients in the
intensively managed arm achieved indi-
vidualtargets(2).IntheSUREstudy,only
61%ofpatientsinthestructuredcarearm
reached 3 targets. This should not dis-
courage us from striving to meet the tar-
gets but, rather, spur us on to ﬁnd new
and better ways of delivering care.
What do these studies tell us about
care delivery? The intensively treated arm
of the Steno-2 study included care pro-
vided by a multidisciplinary, secondary
care team of diabetes specialists in a ded-
icated diabetes center, delivering target-
driven, prespeciﬁed, multiple risk factor
interventions (1). The conventionally
managed arm was treated in a primary
care setting, following the recommenda-
tions of the Danish Medical Association.
The SURE study compared specialist care
and usual general care, both within the
secondary care service. Whether care is
provided as primary or secondary care is
probably not important. What is vital is
that care is delivered by a multidisci-
plinary team of diabetes specialists that is
fully trained and has appropriate skills to
provide all aspects of diabetes manage-
ment. Prespeciﬁed guidelines and proto-
cols, agreed on by all and followed by all
team members, are undoubtedly impor-
tant. Speciﬁcation of treatment targets,
agreed on by patients and professionals
on an individual basis, is essential. A de-
cision not to aim for a recognized tight
treatment target must not happen by de-
fault but must be openly discussed and
justiﬁed. However, even with these mea-
sures, targets are not met uniformly in ev-
eryone. Clinical inertia, patient and
professional reluctance to intensify man-
agement,and,onoccasion,lackofappro-
priate tools and knowledge all contribute
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case-report book was used that was simi-
lar to those in a research study. This may
have helped to prompt change, overcome
clinical inertia, and thus improve the
achievement of targets. A similar, comput-
er-basedinteractivesystemmightbeworth-
while. Efforts to keep health care pro-
fessionals up to date, enthusiastic, and
involved are crucial; regular audits, bench-
markingofservices,andfeedbackareessen-
tial.IntheU.K.,modestﬁnancialincentives
in primary care have improved process and
outcome care measures (9), although the
qualifying targets have not yet been as strict
as those required for high-risk patients. In-
tensive management is onerous for the per-
son with diabetes. Measures to improve
concordance with therapy and to empower
patients—such as regular telephone calls
(10), text messaging (11), and structured
education (12)—are also needed.
Is provision of such high-intensity
care cost-effective? In Europe, hospital
admissionsaccountfor55%ofhealthcare
costsassociatedwithtype2diabetes(13),
and in patients with both microvascular
and macrovascular complications, the to-
tal cost of management is increased by up
to 250% compared with those without
complications (14). In the U.S., an esti-
mated 58 billion USD, (half of the total
annual cost of diabetes care) is spent on
managing diabetes-related chronic com-
plications (15). One model suggests that
myocardial infarction, heart failure, and
renal disease (all of which can be reduced
by multifactorial intervention) have the
greatest ﬁscal impact (16). Economic
analysisoftheSteno-2studysuggeststhat
in the Danish health care system, inten-
sive therapy was more cost-effective than
conventional therapy, with an incremen-
tal cost-effectiveness ratio of 2,538 Euro/
quality-adjusted life-year gained (17).
The increased costs of intensive care were
due to increased pharmacy and consulta-
tion costs. Pharmacy costs can be mini-
mized by prescribing generic drugs.
When both intensive and conventional
care were delivered in primary care, then
intensive therapy became cost saving and
lifesaving.
Of type 2 diabetic patients, 25–50%
have microalbuminuria or more severe
chronic kidney disease and are therefore
atextremelyhighriskforCVDandESRD.
We now have irrefutable evidence that
their prognosis can be greatly improved
by intensive structured care targeting
multiple risk factors and delivered by
multidisciplinary, specialist diabetes
teams. Such care is cost-effective. The
challenge to all health care providers,
now, is to develop systems of care
whereby all high-risk patients can access
such high-quality care.
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